<DOC>
	<DOCNO>NCT02392455</DOCNO>
	<brief_summary>This observational study investigate efficacy tolerability Vargatef ( Nintedanib ) plus docetaxel daily routine second-line treatment patient locally advance , metastatic locally recurrent NSCLC . Treatment Vargatef eligible NSCLC patient , treat physician decide initiate treatment Vargatef second line accord local label , observe 24 month . Survial follow-up do end study .</brief_summary>
	<brief_title>VARGADO - Vargatef 2nd-line Therapy Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : age 18 old men woman locally advance , metastastic and/or recurrent NSCLC adenocarcinoma histology vargatef treatment indicate accord Summary Product Characteristics ( SmPC ) first line therapy ; secondline therapy yet start standard 21daycycles docetaxel treatment accord SmPC possible write informed consent Exclusion criterion : contraindication accord SmPC Vargatef Docetaxel one chemotherapy treatment NSCLC palliative set current partcipation clinical trial pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>